What The Document Says

Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients

The atlas below treats this claim as a live state of knowledge: current support, provenance, missing evidence, inconsistencies, and options for growing the model with new sources.

Query: Analyze the document in /Users/sridharmahadevan/Desktop/PDFs/NYTimes_KRAS.pdf

Detailed PSR tables, overlap checks, and JSON files are available below when you want to inspect the model more closely.

Recommended Analysis

Inspect corpus overlap divergence

corpus causal region. Prometheus treats retrieved studies as local evidence for causal claims, then checks whether nearby causal regions agree, drift, or need to remain separated as regime-specific views.

Run the CLI again only when you want to build a new state.

Causal Atlas Model

From retrieved studies to persistent causal state

provisional

1. Local causal region corpus causal region

Literature-derived causal claims are organized into local contexts such as mechanisms, species or population regimes, measurement issues, ecological pathways, and economic consequences.

2. Topos check 7 divergent restrictions, 0 divergent gluing overlaps

The topos layer asks whether the local views agree. Divergence is kept as useful signal rather than flattened into one sentiment label.

3. Next analysis Inspect corpus overlap divergence

Prometheus uses restriction and gluing diagnostics to identify which causal regions are stable, which are under-supported, and which should be split or inspected as regime-specific.

World Snapshot

Corpus scale and local focus

provisional

Studies1360 extracted causal events

Focus Contextcorpuscorpus

Local PSR332344 histories x 344 tests

Repairs00 overlap-stable

Technical Drill-Downs

Detailed artifacts stay available, but out of the first glance

Use these links when you want the full data dump: finite PSR tables, restriction diagnostics, gluing backpropagation rows, j-do probes, counterfactual lists, and raw JSON.

Open sheaf explorer Open PSR details World-model JSON Data report

Causal Regions

Where the literature evidence lives

breakthrough in pancreatic cancer treatment42 events12% of mapped evidence

breakthrough in cancer drug development39 events11% of mapped evidence

daraxonrasib targeting kras protein36 events10% of mapped evidence

daraxonrasib extends pancreatic cancer survival35 events10% of mapped evidence

metastatic pancreatic cancer treatment32 events9% of mapped evidence

molecular screening for kras binding30 events8% of mapped evidence

challenges targeting kras protein29 events8% of mapped evidence

challenges in targeting kras protein24 events7% of mapped evidence

kras gene mutations and cancer22 events6% of mapped evidence

kras protein as cancer growth driver22 events6% of mapped evidence

Relations

Causal relation mix

Reduces

Causes/Leads/Increases

259

Influences/Affects

Top Aspects

Most frequent causal relations

leads to

146

increases

reduces

influences

causes

affects

Focus PSR

Representative histories and tests

These are the recurring evidence states the local PSR uses as memory and probes. They are shown as readable phrases; the raw state key is still available when useful.

Recent evidence states

sequence boundaryStart of an evidence sequence

causes claimbreakthrough in cancer drug development causes tumor shrinkage in pancreatic cancer patients with kras mutations

Raw state key

breakthrough_in_cancer_drug_development|causes|tumor_shrinkage_in_pancreatic_cancer_patients_with_kras_mutations

increases claimbreakthrough in cancer drug development increases cancer progression by continuously driving tumor growth

Raw state key

breakthrough_in_cancer_drug_development|increases|cancer_progression_by_continuously_driving_tumor_growth

increases claimbreakthrough in cancer drug development increases cancer progression without targeted inhibition

Raw state key

breakthrough_in_cancer_drug_development|increases|cancer_progression_without_targeted_inhibition

increases claimbreakthrough in cancer drug development increases pancreatic cancer progression

Raw state key

breakthrough_in_cancer_drug_development|increases|pancreatic_cancer_progression

Predictive probes

causes claimbreakthrough in cancer drug development causes tumor shrinkage in pancreatic cancer patients with kras mutations

Raw state key

breakthrough_in_cancer_drug_development|causes|tumor_shrinkage_in_pancreatic_cancer_patients_with_kras_mutations

increases claimbreakthrough in cancer drug development increases cancer progression by continuously driving tumor growth

Raw state key

breakthrough_in_cancer_drug_development|increases|cancer_progression_by_continuously_driving_tumor_growth

increases claimbreakthrough in cancer drug development increases cancer progression without targeted inhibition

Raw state key

breakthrough_in_cancer_drug_development|increases|cancer_progression_without_targeted_inhibition

increases claimbreakthrough in cancer drug development increases pancreatic cancer progression

Raw state key

breakthrough_in_cancer_drug_development|increases|pancreatic_cancer_progression

increases claimbreakthrough in cancer drug development increases pancreatic tumor growth

Raw state key

breakthrough_in_cancer_drug_development|increases|pancreatic_tumor_growth

Gluing Diagnostics

Which nearby contexts should be read together?

11 / 18 restrictions 18 / 18 gluing

These diagnostics mark which nearby contexts can be read with corpus and which need separate interpretation. In the full diagnostic set, 7 of 18 observed-overlap checks and 0 of 18 latent gluing checks show tension; the cards below show the strongest examples first.

Observed overlap interpretation

keep separate

daraxonrasib s manageable side effects behaves like a separate regime

daraxonrasib s manageable side effects should not be collapsed into the focus state without inspection: noticeably different transition pattern, with usable shared evidence.

keep separate

daraxonrasib clinical trial outcomes behaves like a separate regime

daraxonrasib clinical trial outcomes should not be collapsed into the focus state without inspection: noticeably different transition pattern, with usable shared evidence.

keep separate

daraxonrasib drug development behaves like a separate regime

daraxonrasib drug development should not be collapsed into the focus state without inspection: noticeably different transition pattern, with usable shared evidence.

keep separate

innovative drug screening methods behaves like a separate regime

innovative drug screening methods should not be collapsed into the focus state without inspection: noticeably different transition pattern, with usable shared evidence.

Latent gluing interpretation

read together

daraxonrasib s manageable side effects travels with the focus state

daraxonrasib s manageable side effects agrees with the focus state closely enough to read them together: small latent mismatch, across a small shared section set.

read together

innovative drug screening methods travels with the focus state

innovative drug screening methods agrees with the focus state closely enough to read them together: small latent mismatch, across a small shared section set.

read together

daraxonrasib drug development travels with the focus state

daraxonrasib drug development agrees with the focus state closely enough to read them together: small latent mismatch, across a small shared section set.

read together

daraxonrasib clinical trial outcomes travels with the focus state

daraxonrasib clinical trial outcomes agrees with the focus state closely enough to read them together: small latent mismatch, across a small shared section set.

Show detailed overlap rows

Restriction checks

Overlap	Status	Gap	Support
corpus -> daraxonrasib s manageable side effects	divergent	max gap 0.5971	9 shared cells
corpus -> daraxonrasib clinical trial outcomes	divergent	max gap 0.4971	16 shared cells
corpus -> daraxonrasib drug development	divergent	max gap 0.4971	16 shared cells
corpus -> innovative drug screening methods	divergent	max gap 0.4971	16 shared cells
corpus -> overcoming decades of drug discovery failures	divergent	max gap 0.4971	16 shared cells
corpus -> pancreatic lung and colon cancer linkage	divergent	max gap 0.4971	16 shared cells

Gluing overlaps

Overlap	Status	Loss	Support
corpus -> daraxonrasib s manageable side effects	aligned	weighted loss 0.0688	3 sections
corpus -> innovative drug screening methods	aligned	weighted loss 0.0489	4 sections
corpus -> daraxonrasib drug development	aligned	weighted loss 0.0462	4 sections
corpus -> daraxonrasib clinical trial outcomes	aligned	weighted loss 0.0402	4 sections
corpus -> potential applications in lung and colon cancers	aligned	weighted loss 0.0369	4 sections
corpus -> overcoming decades of drug discovery failures	aligned	weighted loss 0.0368	4 sections

Research Follow-Up Probes

Focus-context repairs

For literature claim models, counterfactual repair probes are secondary; the useful signal is the local PSR support plus restriction and gluing tension across causal regions.

No focus-context repair probes were attached.

State Reasons

corpus has 7 divergent restriction check(s)

Recommended Actions

Inspect corpus overlap divergence

corpus has 7 divergent restriction check(s)

{
  "context_id": "corpus"
}